Dismiss Notice
Thanks for being a member of our community. Please donate toward site expenses if you can.

Merck's molnupiravir not as effective as initially found

Discussion in 'Coronavirus Pandemic Discussions' started by CenterField, Nov 26, 2021.

Posts do not contain medical or professional advice. Seek reliable alternate sources to verify information you read in this forum.

  1. CenterField

    CenterField Well-Known Member Past Donor

    Joined:
    Jul 21, 2020
    Messages:
    9,882
    Likes Received:
    8,405
    Trophy Points:
    113
    Gender:
    Male
    Merck now has the full data of its molnupiravir trial. The interim results had suggested an efficacy of 50% reduction in hospitalizations and death but the complete set of data ended up with 30% efficacy, which is disappointing.

    Interim data for the Pfizer one had an efficacy of 89%. Let's hope that one doesn't also show a drop in efficacy once the full data are in.
     
    CenterField, Nov 26, 2021
    #1

Share This Page